Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Navafenterol - AstraZeneca

Next Previous
Drug Profile

Navafenterol - AstraZeneca

Alternative Names: AZD-8871; LAS-191351 - AstraZeneca; Navafenterol saccharinate

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Almirall S.A.
  • Developer Almirall S.A.; AstraZeneca
  • Class Acetic acids; Antiasthmatics; Antibronchitics; Esters; Quinolines; Small molecules; Thiazoles; Triazoles
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 03 Mar 2023 Discontinued - Phase-II for Chronic obstructive pulmonary disease in Germany, United Kingdom (Inhalation) due to strategic reasons(AstraZeneca pipeline, February 2023)
  • 17 Sep 2019 Discontinued - Phase-I for Asthma in United Kingdom (Inhalation)
  • 17 Sep 2019 AstraZeneca announces intention to submit regulatory applications for Chronic obstructive pulmonary disease in USA, European Union, Japan and China
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top